Novavax cuts 2024 revenue forecast

Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales
Novavax cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell the shot to Sanofi. The U.S. vaccine maker now expects between $175 million and $225 million for full-year sales of its COVID vaccine,
Novavax sees weak Covid vaccine sales, convinced Sanofi can do better
Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals and a pipeline of new vaccines it's now evaluating for R&D.
Novavax falls after guidance cut on lower vaccine sales
Novavax (NASDAQ:NVAX) shares lost ~12% in the premarket on Tuesday after the Gaithersburg, MD-based biotech, with its Q3 2024 financials, cut its full-year revenue guidance, citing a gloomy sales outlook for its COVID-19 vaccine,
Novavax to Move Forward With Covid-19-Flu Vaccine After FDA Lifts Clinical Hold -- Update
Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, Sanofi will have the sole right to use Novavax's existing Covid-19 vaccine in combination with its own flu vaccine.
FDA Gives Green Signal To Novavax's COVID-19-Influenza Combo Vaccine Late-Stage Trial
On Monday, the FDA removed the clinical hold on Novavax Inc.’s (NASDAQ:NVAX) Investigational New Drug (IND) application for its COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates.
Why Is COVID-19 Vaccine Maker Novavax Stock Trading Lower On Wednesday?
On 1, Novavax, Inc. (NASDAQ:NVAX) and the U.K. Health Security Agency, representing the U.K. Secretary of State for Health and Social Care, signed a Termination and Settlement Agreement and an amendment to resolve disputes over their updated COVID-19 vaccine supply contract from July 1,
FDA clears Novavax to resume trials of Covid-19 and flu combo vaccine
The FDA agreed for Novavax to continue trials of its vaccine combo after addressing a serious adverse event that paused trials.
Forbes on MSN2h
Moderna And Other Vaccine Maker Stocks Tumble After Trump Taps RFK Jr. As HHS Head
Stocks linked to vaccine developers such as Moderna ... RFK Jr., who repeatedly promoted the debunked theory that vaccines ...
Business Insider1d
Novavax Advances Vaccine Strategy Amid Financial Shifts
In its recent third-quarter 2024 earnings report, Novavax highlighted significant advancements in its vaccine portfolio, including the removal of a clinical hold by the U.S. FDA on its ...
AOL2d
Novavax stock plunges after quarterly earnings, but company sees hope in licensing deals
Novavax's COVID-19 vaccine continues to be its only commercial product and currently has about 2%-3% market share, ...
Novavax, UK terminate vaccine supply agreement
Novavax said on Tuesday that it has entered into a termination and settlement agreement with the UK Health Security Agency ...
Novavax: Navigating Fiscal Challenges and Strategic Shifts Amid COVID Vaccine Market Uncertainty
In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...